Home › Acute Lymphoblastic Leukemia › NCT03633955
Pilot Imaging Study of Leukemia
Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging
Who can join
Ages 4 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Aged 4 to 80 years 2. Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma 3. Karnofsky/Lansky score of ≥ 50 4. Agree to use contraceptive measures during study protocol participation (when age appropriate) 5. Patient or parent/guardian capable of providing informed consent. 6. Ability to undergo 18F FLT imaging without sedation 7. Bilirubin \< 2.5 mg/dL, AST/ALT \<5x upper limit of normal, Serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher) 8. Pulse oximetry of \> 90% on room air 9. Ability to undergo 18F FLT imaging without sedation 10. Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy). Exclusion Criteria: 1. Patients with uncontrolled infections 2. Pregnancy or lactating 3. History of prior fluorothymidine allergy or intolerance.
About the study
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
What is being tested
- FLT (drug)
Sponsor: University of Oklahoma · Participants: 60 · Started: Jan 19, 2023
Contact the study team
- Heme Onc Lead Nurse · Phone: 1-405-271-8777
Official record on ClinicalTrials.gov — NCT03633955
Locations in the U.S.
| Georgia | Emory University, Atlanta (Not yet recruiting) |
| Oklahoma | University of Oklahoma Health Sciences Center, Oklahoma City |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.